Lung scan-guided radiation planning for adults with lung cancer
Tests a lung scan to spare working lung tissue during radiation.
Plain-language title generated from the registry record
Registry title: Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer
Key facts
- Where
- Sydney, AustraliaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with small-cell or non-small cell lung cancer who are referred for radiotherapy aimed at removing all of the disease, with or without chemotherapy at the same time.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Lung cancer (small-cell or non-small cell) confirmed under the microscope. People whose few distant spots were removed by surgery or radiotherapy can join.
- Earlier treatment
- Must not have had earlier radiotherapy to the chest. Must not be getting immunotherapy at the same time.
Main reasons for not taking part
- Immunotherapy at the same time
- Earlier radiotherapy to the chest
- Other cancer that is not under control
- Psychological, family, social or geographical conditions that could make it hard to follow the study plan
Read by machine on 12 November 2026.
Where in Australia
- Sydney West Radiation Oncology Network Westmead and Blacktown HospitalsSydney, AustraliaContact: Eric Hau, MBBS PhD FRANZCRTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Aarhus
- Trial code
- NCT04676828
- Record updated
- 24 February 2026
- Original description
Study aims to determine if functional lung avoidance based on perfusion single photon emission (SPECT)/CT scan, improves toxicity outcomes for patients with advanced lung cancer undergoing chemo-radiotherapy. Functional avoidance implies a dose plan that takes functional distribution in the lung into account, and avoids highly functional lung volumes sparing them from radiation.Read full original descriptionShow less
Functional Lung Avoidance SPECT-guided (ASPECT) Radiation Therapy for Lung Cancer Patients: Phase II Randomised Clinical Trial
Study aims to determine if functional lung avoidance based on perfusion single photon emission (SPECT)/CT scan, improves toxicity outcomes for patients with advanced lung cancer undergoing chemo-radiotherapy. Functional avoidance implies a dose plan that takes functional distribution in the lung into account, and avoids highly functional lung volumes sparing them from radiation.
Inclusion: histologically verified lung cancer (small-cell and non-small cell lung cancer); referred for radiotherapy with curative intent; radiation dose of 60-66 Gy given in 2-Gy fractions, other dose levels and fractionation schedules accepted, as per site standard; concurrent chemotherapy is accepted; patients with oligometastatic disease are allowed, where metastasis have been ablated with surgery or radiotherapy; receiving (chemo)-radiotherapy to the thoracic disease with curative intent; adults over 18, that have given oral and written informed consent before patient registration.
Exclusion: concurrent immunotherapy; previous radiotherapy to the thorax; other uncontrolled malignancies; any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol.